AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15675986 — intervention group
Group type: COMPARATOR
Intervention: L3/4H group (4 mg hyperbaric bupivacaine, horizontal)
Number of subjects: 123
Study 15675986 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 123
Study 11869921 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone notification
Number of subjects: 351
Study 11869921 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face notification
Number of subjects: 351
Study 10432476 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose naloxone administered immediately before ECT
Number of subjects: 0
Study 10432476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose naloxone
Number of subjects: 0
Study 10432476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10432476 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose naloxone
Number of subjects: 0
Study 7488341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 6
Study 7488341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 6
Study 7488341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Cyproheptadine and Ketotifen
Number of subjects: 6
Study 31354858 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingshen Granules (QSG), 10 g oral doses, 3 times a day for 12 weeks
Number of subjects: 84
Study 31354858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 31354858 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingshen Granules (QSG)
Number of subjects: 84
Study 30480595 — intervention group
Group type: EXPERIMENTAL
Intervention: ORTSD fixation
Number of subjects: 60
Study 30480595 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 60
Study 26952241 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <45 years
Number of subjects: 7141
Study 26952241 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 45 to <55 years
Number of subjects: 7141
Study 26952241 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 7141
Study 26952241 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥55 years
Number of subjects: 7141
Study 26952241 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <55 years
Number of subjects: 7141
Study 25310118 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous quality improvement/Breakthrough Series intervention
Number of subjects: 32
Study 25310118 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 32
Study 22545736 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-based maintenance intervention
Number of subjects: 165
Study 19772799 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX information booklet (active-arm)
Number of subjects: 78
Study 19772799 — intervention group
Group type: COMPARATOR
Intervention: Control-arm (no MTX information booklet)
Number of subjects: 78
Study 17326150 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose treatment for 3 months (n=31)
Number of subjects: 90
Study 17326150 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, n=30)
Number of subjects: 90
Study 15465941 — intervention group
Group type: EXPERIMENTAL
Intervention: Open access system for outpatient appointments
Number of subjects: 30
Study 15465941 — intervention group
Group type: COMPARATOR
Intervention: Fixed outpatient appointments
Number of subjects: 30
Study 11465625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low preoperative serum antiendotoxin core antibody (EndoCAb) concentration
Number of subjects: 1056
Study 11465625 — intervention group
Group type: EXPERIMENTAL
Intervention: POSSUM physiologic risk score
Number of subjects: 1056
Study 11465625 — intervention group
Group type: EXPERIMENTAL
Intervention: Total immunoglobulin M and total immunoglobulin G concentrations
Number of subjects: 1056
Study 9740922 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution (0.9% sodium chloride)
Number of subjects: 0
Study 7979616 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (500 cGy)
Number of subjects: 301
Study 7979616 — intervention group
Group type: COMPARATOR
Intervention: No preoperative therapy
Number of subjects: 301
Study 3055924 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine-propranolol combination therapy
Number of subjects: 19
Study 3055924 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem-propranolol combination therapy
Number of subjects: 19
Study 3055924 — intervention group
Group type: COMPARATOR
Intervention: High dose diltiazem monotherapy
Number of subjects: 19
Study 4808815 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg)
Number of subjects: 20
Study 4808815 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg)
Number of subjects: 20
Study 4808815 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ethanol (combined)
Number of subjects: 20
Study 4808815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 20
Study 4808815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium acetylsalicylate
Number of subjects: 20
Study 4808815 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 20
Study 4808815 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone
Number of subjects: 20
Study 4808815 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 20
Study 4808815 — intervention group
Group type: COMPARATOR
Intervention: Long-term aspirin and prednisone (patients)
Number of subjects: 20
Study 30884986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab with trastuzumab and chemotherapy (THP)
Number of subjects: 0
Study 30884986 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab and chemotherapy (TH)
Number of subjects: 0
Study 28088957 — intervention group
Group type: EXPERIMENTAL
Intervention: Subserosal injection of carbon nanoparticles around the tumor one day before the operation (trial group)
Number of subjects: 78
Study 28088957 — intervention group
Group type: COMPARATOR
Intervention: Routine laparoscopic gastrectomy (control group)
Number of subjects: 78
Study 28088957 — intervention group
Group type: EXPERIMENTAL
Intervention: Subserosal injection of carbon nanoparticles (trial group)
Number of subjects: 78
Study 25155895 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy monitoring (DTMG)
Number of subjects: 200
Study 25155895 — intervention group
Group type: COMPARATOR
Intervention: Health education (HEG)
Number of subjects: 200
Study 23394573 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support in the provision of brief lifestyle assessments and interventions
Number of subjects: 129
Study 23394573 — intervention group
Group type: COMPARATOR
Intervention: Control group provided usual care
Number of subjects: 129
Study 21477065 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP (1 or 2 mg glimepiride, 500 mg sustained-release metformin, and 15 mg pioglitazone administered once daily)
Number of subjects: 101
Study 21477065 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP
Number of subjects: 101
Study 21477065 — intervention group
Group type: COMPARATOR
Intervention: IM (human insulin 70/30 mix and 500 mg sustained-release metformin administered twice daily)
Number of subjects: 101
Study 21477065 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP and IM
Number of subjects: 101
Study 21477065 — intervention group
Group type: COMPARATOR
Intervention: IM
Number of subjects: 101
Study 18094223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate hydrofluoroalkane 88 mug twice a day
Number of subjects: 79
Study 18094223 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate chlorofluorocarbon 88 mug twice a day
Number of subjects: 79
Study 18094223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 17052048 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 14603059 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium implants
Number of subjects: 0
Study 14603059 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactide resorbable plates
Number of subjects: 0
Study 14603059 — intervention group
Group type: COMPARATOR
Intervention: Silicone pressure equalizing tube
Number of subjects: 0
Study 10813165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nail (IMN)
Number of subjects: 44
Study 10813165 — intervention group
Group type: COMPARATOR
Intervention: Dynamic compression plate (DCP)
Number of subjects: 44
Study 8985795 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived overprotectiveness by wives
Number of subjects: 52
Study 8985795 — intervention group
Group type: EXPERIMENTAL
Intervention: Wives' perception of overprotectiveness
Number of subjects: 52
Study 8985795 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' perception of overprotectiveness at 3 months
Number of subjects: 52
Study 1476280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg orally 1 hour before surgery
Number of subjects: 60
Study 1476280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6086466 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution containing 2.94 g sodium citrate per litre
Number of subjects: 40
Study 6086466 — intervention group
Group type: COMPARATOR
Intervention: WHO recommended oral rehydration solution containing 2.5 g sodium bicarbonate per litre
Number of subjects: 40
Study 6086466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sodium citrate and sodium bicarbonate solutions
Number of subjects: 40
Study 30371826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 205
Study 30371826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment + Contingency Management (CBT + CM)
Number of subjects: 205
Study 29948355 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 44
Study 29948355 — intervention group
Group type: COMPARATOR
Intervention: Splinting
Number of subjects: 44
Study 26260038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowered threshold group
Number of subjects: 2
Study 26260038 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised threshold group
Number of subjects: 2
Study 26260038 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 24761794 — intervention group
Group type: EXPERIMENTAL
Intervention: exoU(+) strains
Number of subjects: 0
Study 24761794 — intervention group
Group type: COMPARATOR
Intervention: exoU(‐) strains
Number of subjects: 0
Study 24761794 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections involving resistant exoU(+) strains
Number of subjects: 0
Study 24761794 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory isolates with exoU gene modification
Number of subjects: 0
Study 21770835 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high doses parenteral nutrition (3.0 g/kg/day amino acids and 3 g/kg/day of 20% lipid)
Number of subjects: 41
Study 21770835 — intervention group
Group type: COMPARATOR
Intervention: Early low dose parenteral nutrition (1 g/kg/day amino acids and lipid, advanced to 3 g/kg/day over 3 days)
Number of subjects: 41
Study 20977130 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral meclizine (experimental group)
Number of subjects: 70
Study 20977130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 70
Study 18834238 — intervention group
Group type: COMPARATOR
Intervention: Free Gingival Graft (FGG)
Number of subjects: 25
Study 18834238 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilayered Cell Therapy (BCT)
Number of subjects: 25
Study 14697473 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day for 6 weeks
Number of subjects: 18
Study 14697473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11897906 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies (aPL) presence in women undergoing IVF‐ET
Number of subjects: 0
Study 11897906 — intervention group
Group type: COMPARATOR
Intervention: Routine screening for aPL
Number of subjects: 0
Study 9834049 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 microg/kg CP‐99,994 infused intravenously over 5 hours on a tapering regimen starting 2 hours before surgery
Number of subjects: 78
Study 9834049 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral ibuprofen 30 minutes before surgery
Number of subjects: 78
Study 9834049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 8077892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 21
Study 8077892 — intervention group
Group type: COMPARATOR
Intervention: Antacid solution
Number of subjects: 21
Study 8077892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2671083 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 26
Study 2671083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 14049 — intervention group
Group type: COMPARATOR
Intervention: neomycin-sorbitol
Number of subjects: 33
Study 14049 — intervention group
Group type: EXPERIMENTAL
Intervention: lactulose
Number of subjects: 33
Study 28527751 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger flexion exercise using elastic resistance
Number of subjects: 18
Study 28527751 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger extension exercise using elastic resistance
Number of subjects: 18
Study 27792023 — intervention group
Group type: EXPERIMENTAL
Intervention: Double straps with the backpack worn midline on the back with one strap over each shoulder
Number of subjects: 18
Study 27792023 — intervention group
Group type: EXPERIMENTAL
Intervention: Single strap with the backpack worn laterally with one strap over the shoulder
Number of subjects: 18
Study 24738319 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable shanching satin rb-bFGF prepreg sheet and expansion hemostatic sponge
Number of subjects: 96
Study 24738319 — intervention group
Group type: COMPARATOR
Intervention: Vaseline gauze nasal packing
Number of subjects: 96
Study 23496212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (2 g/d)
Number of subjects: 64
Study 23496212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20421723 — intervention group
Group type: EXPERIMENTAL
Intervention: Shan 4
Number of subjects: 210
Study 20421723 — intervention group
Group type: COMPARATOR
Intervention: EasyFour
Number of subjects: 210
Study 20421723 — intervention group
Group type: EXPERIMENTAL
Intervention: Shan 4 and EasyFour
Number of subjects: 210
Study 19038901 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly adults (age 65 and older)
Number of subjects: 352
Study 15864218 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 41
Study 15864218 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfusion of ACh plus vitamin C
Number of subjects: 41
Study 15864218 — intervention group
Group type: EXPERIMENTAL
Intervention: l-NMMA (NO-synthase inhibitor)
Number of subjects: 41
Study 15864218 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin (0.4 mg/day)
Number of subjects: 41
Study 12935384 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused coping
Number of subjects: 179
Study 12935384 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since HIV diagnosis
Number of subjects: 179
Study 12935384 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction effect of time and coping
Number of subjects: 179
Study 10759665 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet twice a day for 3 days
Number of subjects: 231
Study 10759665 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ciprofloxacin (500 mg) and tinidazole (600 mg)
Number of subjects: 231
Study 10759665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-tinidazole combination twice a day for 3 days
Number of subjects: 231
Study 8628089 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray
Number of subjects: 30
Study 8628089 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride nasal spray
Number of subjects: 30
Study 8628089 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 30
Study 1466465 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 100 micrograms epinephrine (group 2)
Number of subjects: 47
Study 1466465 — intervention group
Group type: COMPARATOR
Intervention: 3 mg morphine sulfate and 100 micrograms epinephrine in normal saline (group 3)
Number of subjects: 47
Study 1466465 — intervention group
Group type: COMPARATOR
Intervention: Normal saline with 100 micrograms epinephrine (group 1)
Number of subjects: 47
Study 6362815 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin and cyclophosphamide (AC)
Number of subjects: 158
Study 6362815 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (H)
Number of subjects: 158
Study 31565116 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 26 years and above
Number of subjects: 422
Study 31565116 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with good knowledge on breast cancer risk factors
Number of subjects: 422
Study 31565116 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who had ever heard about breast cancer screening
Number of subjects: 422
Study 28893676 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive skill-building activities
Number of subjects: 360
Study 28893676 — intervention group
Group type: COMPARATOR
Intervention: Neutral control activities
Number of subjects: 360
Study 26694939 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg orally with ondansetron 4 mg intravenously
Number of subjects: 125
Study 26694939 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg intravenously
Number of subjects: 125
Study 24566504 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led self-management intervention (Building Recovery of Individual Dreams and Goals Through Education and Support)
Number of subjects: 428
Study 24566504 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 428
Study 21984038 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg)
Number of subjects: 147
Study 21984038 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (100 mg)
Number of subjects: 147
Study 20200816 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methionine (0.1 g/kg)
Number of subjects: 30
Study 20200816 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 30
Study 18991518 — intervention group
Group type: EXPERIMENTAL
Intervention: T'ai chi (TC) exercise, 90-minute sessions weekly for 9 months
Number of subjects: 61
Study 18991518 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily physical activity)
Number of subjects: 61
Study 15767195 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cushions used during mammography
Number of subjects: 394
Study 11815494 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual education
Number of subjects: 170
Study 11815494 — intervention group
Group type: COMPARATOR
Intervention: Group education
Number of subjects: 170
Study 9917122 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators
Number of subjects: 0
Study 9917122 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic medications
Number of subjects: 0
Study 9917122 — intervention group
Group type: COMPARATOR
Intervention: β-blockers or verapamil
Number of subjects: 0
Study 7481022 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 7481022 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 3556261 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pivmecillinam/250 mg pivampicillin given twice daily
Number of subjects: 3783
Study 3556261 — intervention group
Group type: COMPARATOR
Intervention: 250 mg amoxycillin given three times daily
Number of subjects: 3783
Study 30249389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg/day
Number of subjects: 391
Study 30249389 — intervention group
Group type: COMPARATOR
Intervention: Ofatumumab
Number of subjects: 391
Study 30249389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 391
Study 26992879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence therapy (8 sessions)
Number of subjects: 30
Study 26992879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adherence therapy)
Number of subjects: 30
Study 25965108 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercise
Number of subjects: 11
Study 25965108 — intervention group
Group type: COMPARATOR
Intervention: Control (women without PMS)
Number of subjects: 11
Study 23320746 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of diseases
Number of subjects: 733
Study 23320746 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary incontinence
Number of subjects: 733
Study 23320746 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 733
Study 23320746 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrhythmias
Number of subjects: 733
Study 23320746 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 733
Study 23320746 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of diseases (with reference to those with ≤ 1 condition)
Number of subjects: 733
Study 20502133 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (as an adjunct to l-dopa)
Number of subjects: 150
Study 19097508 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous penetration needling
Number of subjects: 66
Study 19097508 — intervention group
Group type: COMPARATOR
Intervention: Straight needling
Number of subjects: 66
Study 20659697 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 1% paste
Number of subjects: 69
Study 20659697 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.043% paste
Number of subjects: 69
Study 16282232 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 4th day bathing (intervention group, n = 25)
Number of subjects: 53
Study 16282232 — intervention group
Group type: COMPARATOR
Intervention: Every other day bathing (control group, n = 28)
Number of subjects: 53